Product Description
Palbociclib is a targeted therapy Known as CDK4/6 inhibitor. Palbociclib is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2(HER2)-negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.